Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy…
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared…
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared…
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use…
-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of…
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the…
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit…
Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage DeterminationCANTON, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE)…
NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The global electronic health records…
WASHINGTON--(BUSINESS WIRE)--#CALiD--Perspectum, a leader in medical imaging quantification techniques, today announced that it has been awarded a 2024 U.S. Food…